Just three and a half years after a clinical trial demonstrating the first successful and sustained use of genetically engineered T cells to fight leukemia, LLS-funded researcher Carl H. June, M.D., and his team at University of Pennsylvania and Children's Hospital of Philadelphia presented more promising results this week at The American Society of Hematology (ASH) conference in New Orleans.The latest results involved both adults and children with advanced leukemias. For these patients, this therapy was the last option available, as all previous therapies had failed. Among the first 59 patients who received this experimental cellular therapy, 89% of patients were cancer free after treatment."These findings show real promise for critically ill patients, who have run out of options. And they clearly demonstrate the ability of LLS-funded researchers to use innovative bioengineering methods to activate the immune system to kill cancer cells." said Lee Greenberger, Ph.D., chief scientific officer of The Leukemia & Lymphoma Society.Because of support from people like you, LLS has been able to invest $15 million in Dr. June's work, with an additional $6 million committed through 2017. Your donations are having a real impact for blood cancer patients today.Watch Dr. June talk more about this breakthrough therapy.LLS needs your continued generosity to ensure access to cures and treatments for patients. Your donations are getting us closer to a world without blood cancers not someday, but today.Thank you,John E. WalterPresident & CEO The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. LLS's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. See how your donations are invested wisely.